A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser Permanente Northern California have identified the first pharmacogenomic marker for anthracyclines and HER2-targeting drugs, two commonly used breast cancer chemotherapies. The results of the large genetic analysis were published today in NPJ Breast Cancer.

Although there have been slight improvements in outcomes after conventional therapy, survival rates remain poor for women with advanced ovarian cancer. Seven researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have been awarded pilot grants from the Ovarian Cancer SPORE to make progress in research for ovarian cancer, the fifth leading cause of cancer death in women.

Roswell Park Comprehensive Cancer Center is proud to announce that Department of Immunology researcher Kathleen Kokolus, PhD, has been named an Irish Echo “40 Under 40” awardee.

Considered the backbone of the hospital and the ones to advocate for patients all while delivering the highest quality care, the Nursing Department at Roswell Park Comprehensive Cancer Center is holding an open house on Tuesday, March 15.